<DOC>
	<DOCNO>NCT00109239</DOCNO>
	<brief_summary>This Phase III , multicenter , randomize , active-controlled , open-label trial design evaluate efficacy , safety , pharmacokinetics rhuMAb VEGF combine capecitabine compare capecitabine alone subject previously treat metastatic breast cancer .</brief_summary>
	<brief_title>A Study rhuMAb VEGF ( Bevacizumab ) Combination With Chemotherapy Patients With Previously Treated Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Written inform consent Women &gt; =18 year age Histologically confirm carcinoma breast metastatic disease currently progress ; subject present metastatic disease , cytologic confirmation permissible Prior administration one two conventional chemotherapy regimens metastatic disease ( Subjects bone marrow peripheral blood stem cell transplantation association chemotherapy eligible study . ) OR No prior chemotherapy metastatic disease subject receive regimen contain anthracycline ( anthracenedione ) taxane adjuvant therapy relapse occur within 12 month complete adjuvant chemotherapy Prior administration anthracycline ( anthracenedione ) taxane either adjuvant metastatic setting Recovery reversible toxicity prior therapy Bidimensionally measurable disease ; least one target lesion must bidimensionally measurable least one target lesion must biopsied recently ; target lesion must &gt; =2 cm long dimension ECOG performance status 0 1 Use effective mean contraception woman childbearing potential Life expectancy &gt; =3 month Willingness capability accessible followup Pleural effusion bone lesion manifestation current metastatic breast cancer Known HER2positive status ( either 3+ immunohistochemistry positive FISH ) , evaluated institution , unless subject previously relapse follow Herceptin ( R ) therapy . Subjects may continue Herceptin therapy enrol trial . Other primary malignancy ( basal cell carcinoma skin situ cervical cancer ) within 5 year precede Day 0 Prior radiotherapy measurable metastatic lesion ( ) use lesion measure response , unless target lesion within radiation field actively progress radiotherapy complete &gt; =6 month prior randomization Radiation therapy , hormonal therapy , biologic therapy , chemotherapy metastatic breast cancer within 21 day prior Day 0 Use bisphosphonates unless initiate least 21 day Day 0 Previous treatment capecitabine Previous treatment rhuMAb VEGF History evidence upon physical examination CNS disease ( e.g. , primary brain tumor , seizures control standard medical therapy , brain metastasis , history stroke ; subject must baseline CT MRI head . ) Serious , nonhealing wound , ulcer , bone fracture Clinically significant cardiovascular disease ( e.g. , uncontrolled hypertension , myocardial infarction , unstable angina ) , New York Heart Association ( NYHA ) Grade II great congestive heart failure , serious cardiac arrhythmia require medication , Grade II great peripheral vascular disease within 1 year prior Day 0 Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study ; fine needle aspiration breast within 7 day prior Day 0 ; placement vascular access device within 7 day prior Day 0 Current recent ( within 10 day prior Day 0 ) use fulldose oral parenteral anticoagulant thrombolytic agent ( except require maintain patency preexisting , permanent indwell IV catheter ; subject receive warfarin , international normalize ratio [ INR ] &lt; 1.5 ; appropriate use heparin discuss Medical Monitor ) Chronic , daily treatment aspirin ( &gt; 325 mg/day ) nonsteroidal antiinflammatory medication ( kind know inhibit platelet function dos use treat chronic inflammatory disease ) Presence bleed diathesis coagulopathy Active infection require parenteral antibiotic Day 0 Pregnancy ( positive pregnancy test ) lactation Proteinuria baseline clinically significant impairment renal function Severe renal impairment ( creatinine clearance &lt; 30 mL/min baseline use CockcroftGault formula ) Known sensitivity 5FU Lack physical integrity upper gastrointestinal tract , know malabsorption significant disease stomach , small intestine , liver , kidney may adversely affect pharmacokinetics capecitabine History allergy iodinecontaining contrast require treatment would prohibit use CT scan contrast Screening clinical laboratory value : *ANC &lt; 1500/uL ; *Platelet count &lt; 75,000/uL ; *INR &gt; =1.5 ; *Total bilirubin &gt; 1.5 time upper limit normal ; *AST ALT &gt; 2.5 time upper limit normal ( &gt; 5 time upper limit normal subject know metastatic disease liver ) ; *Serum creatinine &gt; 2.0 mg/dL ; *Hemoglobin &lt; 9 gm/dL ( may transfuse maintain exceed level ) History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication Current recent ( within 28 day prior Day 0 ) participation another experimental drug study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Cancer</keyword>
</DOC>